10x Genomics (TXG) Q1 2026 earnings review
Core Growth Returns, But CapEx Freeze Persists
10x Genomics delivered a surprisingly solid Q1 on the top and bottom lines. While reported revenue fell 3% YoY to $150.8M, excluding last year's massive patent settlement, core revenue actually grew 9%. This was driven entirely by a resilient consumables business (+13% YoY). The real standout is cost discipline: operating expenses dropped 15%, slashing the net loss by 61% to -$13.5M and allowing cash balances to grow. However, a 24% YoY plunge in instrument sales indicates academic and biopharma CapEx budgets remain firmly frozen, casting a shadow over future placement growth.
🐂 Bull Case
Gross margins expanded to 70% (from 68%), and operating expenses fell $21.6M YoY. The company is proving it can operate efficiently and stem cash burn despite sluggish macro conditions.
Consumables now represent 86% of total revenue and grew 13% YoY. Researchers are actively utilizing the existing installed base, meaning 10x is successfully monetizing its ecosystem.
🐻 Bear Case
Total instrument revenue hit a multi-year low of $11.3M (down 24% YoY). Without new placements, long-term consumable pull-through will eventually stagnate.
Despite 9% core growth in Q1, management maintained FY26 guidance of just 0-4% growth. This implies they expect significant deterioration in the remaining three quarters of the year.
⚖️ Verdict: ⚪
Neutral. The transition to a profitable, consumables-driven model is working, but the sheer collapse in hardware sales and extremely cautious full-year guidance limit any aggressive upside narrative.
Key Themes
Atera Launch Rethinks Spatial Scale
Management announced Atera, engineered for spatial whole-transcriptome analysis with single-cell sensitivity at massive scale. Set to ship in H2 2026, this represents the most significant product introduction in company history, directly targeting the growing demand for mega-scale biological datasets.
Consumables Engine Powers the Top Line
Stable consumable growth is 10x's lifeboat. Consumables grew 13% YoY to $129.8M. Spatial consumables were the standout, surging 31% YoY ($40.9M vs $31.2M), validating the company's prior strategic pivot toward Xenium utilization.
Ruthless OpEx Control Pays Off
Following an 8% workforce reduction announced early last year, operating expenses declined 15% YoY to $123.2M (down from $144.8M). This allowed the company's net loss to compress dramatically to just -$13.5M, down from -$34.4M in the prior year period.
The Instrument Ice Age Continues
The macro capital expenditure environment remains severely depressed. Instrument revenue decelerated further, dropping 24% YoY to just $11.3M. Both Single Cell ($5.2M) and Spatial ($6.0M) hardware faced sharp YoY declines, confirming that academic and biopharma customers are delaying large capital outlays.
Guidance Contradicts Positive Q1 Narrative
A major red flag: 26Q1 core revenue grew 9%, but management strictly maintained FY26 guidance of 0-4% growth (ex-settlements). Mathematically, this means the company expects revenue growth to decelerate sharply—potentially turning flat or negative—over the next three quarters. The 'solid start' is not expected to last.
Single Cell Transition Caps Growth
While overall consumables grew 13%, Single Cell consumables grew a more modest 6% YoY ($88.9M vs $84.1M). As noted in prior quarters, the success of the lower-cost FLEX APEX assay is driving massive reaction volume growth but cannibalizing higher-priced legacy kits, acting as a permanent pricing headwind for this segment.
Other KPIs
Accelerating. Up from 68% in 25Q1. This improvement was driven by lower warranty costs and lower inventory write-downs, proving that the company is moving past previous manufacturing and supply chain inefficiencies.
Accelerating. The EMEA region posted 16% YoY growth (up from $31.9M), showing resilient regional demand that outpaced the Americas (which was heavily skewed by last year's litigation settlement).
Stable and improving. Cash balances increased by $16.4M sequentially from $523.4M at the end of 25Q4. This marks a critical inflection point: the company's cost cuts have effectively halted cash burn, providing a massive runway to weather the CapEx storm.
Guidance
Decelerating. The midpoint of $612.5M implies roughly 2.3% YoY growth compared to FY25's adjusted revenue of $598.7M. Given that Q1 just delivered 9% core growth, this guidance expects a severe slowdown in Q2-Q4, reflecting persistent caution regarding U.S. academic funding and capital equipment demand.
Key Questions
Atera Cannibalization Effect
With the announcement of the Atera platform shipping in H2 2026, are you anticipating an immediate 'freeze' in Xenium instrument purchases as customers wait for the new technology?
Reconciling Q1 Beat vs FY Guidance
You achieved 9% core growth this quarter, yet maintained an annual guide of 0-4%. Are you seeing concrete evidence of order cancellations for Q2/Q3, or is this guide purely a buffer against macro uncertainty?
Instrument Revenue Floor
Instrument revenue dropped to $11.3M this quarter. Is this the absolute baseline required just to replace aging fleets, or is there still further downside risk if academic funding remains bottlenecked?